New schizophrenia drug Abilify to lead the market by 2016

29 December 2013

Long-acting depot therapy Abilify Maintena (aripiprazole) will become the leading injectable schizophrenia therapy by 2016, predicts independent analyst firm Datamonitor Healthcare.

The drug from Japan’s Otsuka Pharmaceutical (TYO: 4768) and Danish CNS specialist Lundbeck (LUN: CO) received approval from the European Commission in November for maintenance treatment of schizophrenia in adult patients stabilized with oral aripiprazole. The once-monthly version of Otsuka’s $7 million-a-year standard Abilify was approved by the US Food and Drug Administration earlier this year (The Pharma Letter March 1).

Strong competition due to tolerability

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK